Loss of Y chromosome in blood is associated with major cardiovascular events during follow-up in men after carotid endarterectomy

S Haitjema, D Kofink, J Van Setten… - Circulation …, 2017 - Am Heart Assoc
S Haitjema, D Kofink, J Van Setten, SW Van Der Laan, AH Schoneveld, J Eales
Circulation: Cardiovascular Genetics, 2017Am Heart Assoc
Background—Recent studies found an immune regulatory role for Y chromosome and a
relationship between loss of Y chromosome (LOY) in blood cells and a higher risk of cancer
and mortality. Given involvement of immune cells in atherosclerosis, we hypothesized that
LOY is associated with the severity of atherosclerotic plaque characteristics and outcome in
men undergoing carotid endarterectomy. Methods and Results—LOY was quantified in
blood and plaque from raw intensity genotyping data in men within the Athero-Express …
Background
Recent studies found an immune regulatory role for Y chromosome and a relationship between loss of Y chromosome (LOY) in blood cells and a higher risk of cancer and mortality. Given involvement of immune cells in atherosclerosis, we hypothesized that LOY is associated with the severity of atherosclerotic plaque characteristics and outcome in men undergoing carotid endarterectomy.
Methods and Results
LOY was quantified in blood and plaque from raw intensity genotyping data in men within the Athero-Express biobank study. Plaques were dissected, and the culprit lesions used for histology and the measurement of inflammatory proteins. We tested LOY for association with (inflammatory) atherosclerotic plaque phenotypes and cytokines and assessed the association of LOY with secondary events during 3-year follow-up. Of 366 patients with carotid endarterectomy, 61 exhibited some degree of LOY in blood. LOY was also present in atherosclerotic plaque lesions (n=8/242, 3%). LOY in blood was negatively associated with age (β=−0.03/10 y; r2=0.07; P=1.6×10–7) but not with cardiovascular disease severity at baseline. LOY in blood was associated with a larger atheroma size (odds ratio, 2.15; 95% confidence interval, 1.06–4.76; P=0.04); however, this association was not significant after correction for multiple testing. LOY was independently associated with secondary major cardiovascular events (hazard ratio=2.28; 95% confidence interval, 1.11–4.67; P=0.02) in blood when corrected for confounders.
Conclusions
In this hypothesis-generating study, LOY in blood is independently associated with secondary major cardiovascular events in a severely atherosclerotic population. Our data could indicate that LOY affects secondary outcome via other mechanisms than inflammation in the atherosclerotic plaque.
Am Heart Assoc